Related Experiment Video
Updated: Aug 15, 2026
08:32
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
The connections between C75 and obesity drug-target pathways
Francis P Kuhajda1, Leslie E Landree, Gabriele V Ronnett
1Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. fkuhajda@jhmi.edu
Trends in Pharmacological Sciences
|September 20, 2005
Summary
C75, a fatty acid synthase inhibitor, causes weight loss in mice by affecting fatty acid synthesis and oxidation. New data challenges the link between fatty acid synthase inhibition and C75-induced anorexia.
Area of Science:
- Biochemistry
- Metabolism
- Obesity Research
Background:
- Obesity and Type II diabetes are global epidemics.
- C75, a fatty acid synthase (FAS) inhibitor, induces significant weight loss in mice.
- C75 also stimulates carnitine palmitoyl 1 activity, impacting fatty acid oxidation.
Purpose of the Study:
- To explore the mechanisms behind C75-induced weight loss.
- To investigate the role of fatty acid synthesis and oxidation in obesity therapy.
- To present recent findings that question the established link between FAS inhibition and C75-induced anorexia.
Main Methods:
- Review of latest scientific data and research findings.
- Analysis of C75's effects on fatty acid metabolism in preclinical models.
- Examination of the relationship between fatty acid synthase inhibition and appetite regulation.
Main Results:
- C75 effectively reduces body weight in mice.
- The compound impacts both fatty acid synthesis and oxidation pathways.
- Emerging evidence suggests a complex relationship between FAS inhibition and anorexia.
Conclusions:
- C75 serves as a valuable tool for understanding obesity pathways.
- Targeting fatty acid synthesis and oxidation are potential therapeutic strategies for obesity.
- The direct link between fatty acid synthase inhibition and C75-induced anorexia requires further investigation.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:19Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include: